Are AgNORs useful in distinguishing follicular hyperplasia from follicular lymphoma?

K CRONIN, BARBARA M LOFTUS, P A DERVAN

From the Department of Pathology, Mater Misericordiae Hospital and University College, Dublin, Eire

SUMMARY Argyrophilic nucleolar organiser regions (AgNORs) in 28 follicular lymphomas and 30 lymph nodes showing reactive follicular hyperplasia were studied to see if they were helpful in distinguishing follicular lymphoma from follicular hyperplasia in paraffin wax tissue sections. Mean nuclear counts were greater in follicular hyperplasia (3.71 ± 3.11). This difference was significant but counts overlapped so much that they were of no practical value in distinguishing between both conditions. Higher counts may reflect greater proliferative activity in follicular hyperplasia.

AgNORs have been of theoretical interest to cytogeneticists. Recent reports on the quantification of AgNORs in a variety of tumours have kindled general interest in nucleoli and AgNOR abnormalities in surgical pathology, and in their practical diagnostic usefulness. In almost all of these studies malignant tumours were found to contain more AgNORs than their benign counterparts.

The demonstration of follicular monotypic light chain staining distinguishes follicular lymphoma from follicular hyperplasia. Surgical pathologists, however, are occasionally faced with a difficult problem of distinguishing these histologically similar proliferations in routinely processed formalin fixed paraffin wax sections (with no fresh tissue available for κ and λ immunostaining or gene rearrangement studies). To see if quantification of AgNORs might be of value in distinguishing follicular lymphomas from reactive follicular hyperplasia in paraffin wax sections we compared AgNOR counts in both conditions. To see if AgNOR counts might be related to nuclear size we also compared nuclear diameters in both conditions and correlated AgNOR counts with nuclear diameter.

Material and methods

Random follicles from 28 cases of follicular lymphoma (mixed, small cleaved, and large cell/centroblastic-centrocytic) and from 30 lymph nodes showing reactive follicular hyperplasia were examined. These were diagnosed by conventional light microscopy on haematoxylin and eosin stained sections. All specimens were fixed in formalin. Paraffin wax sections (4 μm thick) were stained for AgNORs as described by Crocker. One hundred follicular cells from each case were examined using an oil immersion objective (× 100) and a × 10 eyepiece (total magnification × 1000). Nuclear diameters were also recorded for each cell examined. Using a calibrated eyepiece, the long and short axes of each nucleus were measured. As the shape of the nuclei approximated to a circle the diameter was recorded as the average of the long and short axis. Correlation between nuclear diameter and counts was carried out using Pearson's

![Graph showing AgNOR counts in follicular cells in follicular hyperplasia and follicular lymphoma. Plus sign denotes mean count ± 1 standard deviation.](http://jcp.bmj.com/)

Accepted for publication 13 July 1989
correlation coefficient, and significance of intergroup mean counts was estimated with Student’s t test.

Results

The difference between AgNOR counts in follicular hyperplasia and follicular lymphoma was significant (p < 0.01). Follicular cells from reactive hyperplasia had a mean of 3.71 nuclear AgNORs per case (standard deviation, 0.83; median, 3.59; and range, 2.02–5.52). Follicular lymphomas had a mean of 3.11 (standard deviation, 0.9; median, 2.91; and range, 1.62–5.4). Counts in both conditions showed considerable overlap (fig 1). Follicular hyperplasias and follicular lymphomas showed no significant difference in mean nuclear diameters (7.13, SD 0.68 v 7.17, SD 0.90). There was no correlation between AgNOR counts and nuclear diameter (r = 0.08; P = 0.5).

Discussion

In many studies malignant cells contain more AgNORs than benign proliferations. Nevertheless, the practical diagnostic value of AgNOR counts in borderline or difficult lesions has not been shown.2

In this study the difference between mean counts in both groups was significant (t test p < 0.01); there was no correlation between counts and nuclear diameter. These results are not useful, however, from a practical point of view, as there was too much overlap between counts. This lack of diagnostic value is clearly shown in the receiver operating characteristic (ROC) curve in fig 2. In the ROC curve, a good diagnostic test with high sensitivity and high specificity will have the curvature located in the top left-hand corner of the plot.10

Interestingly, counts were higher in the group with reactive hyperplasia. This raises the possibility that increased numbers of AgNORs may reflect cell proliferation rather than biological malignancy. Hall has shown that AgNOR counts correlate with proliferative activity in malignant lymphomas, as assessed by Ki67 scores.11 Recently, we12 and Giri13 have shown a similar correlation in breast cancer. Weiss has shown that follicular hyperplasia shows greater proliferative activity than follicular lymphoma.14 Most follicular lymphomas are low grade lymphomas, possibly with low cell proliferation, whereas hyperplastic follicles are highly active units, as can be seen in any reactive lymph node immunostained with monoclonal antibody Ki67.

Estimation of AgNOR counts may prove of diagnostic value in some specific situations and possibly they may be helpful in obtaining cell kinetic information in paraffin wax sections.12 They are of no value, however, in distinguishing follicular hyperplasia from follicular lymphoma.

This study was supported by the Health Research Board, Eire.

References


Requests for reprints to: Dr P A Dervan, Pathology Department, Mater Misericordiae Hospital, Eccles Street, Dublin, Eire.
Are AgNORs useful in distinguishing follicular hyperplasia from follicular lymphoma?

K Cronin, B M Loftus and P A Dervan

doi: 10.1136/jcp.42.12.1267

Updated information and services can be found at: [http://jcp.bmj.com/content/42/12/1267](http://jcp.bmj.com/content/42/12/1267)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)